| P50 | author | Keith Channon | Q56420294 |
| P2093 | author name string | Charalambos Antoniades | |
| | Marios Margaritis | |
| | Regent Lee | |
| | Alexios S Antonopoulos | |
| P2860 | cites work | C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study | Q24617734 |
| | Atherosclerosis — An Inflammatory Disease | Q26776972 |
| | Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study | Q28186001 |
| | Statins in the treatment of chronic heart failure: a systematic review | Q28200294 |
| | MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 |
| | Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 |
| | Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) | Q29547825 |
| | The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 |
| | Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study | Q29617822 |
| | Intensive versus moderate lipid lowering with statins after acute coronary syndromes | Q29619716 |
| | Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group | Q29619842 |
| | Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 |
| | Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures | Q30318772 |
| | Apoptosis contributes to septic cardiomyopathy and is improved by simvastatin therapy | Q30319507 |
| | Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance | Q31796937 |
| | Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project | Q31829457 |
| | Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization | Q31956534 |
| | Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction | Q33331962 |
| | Simvastatin improves endothelial function in patients with rheumatoid arthritis | Q45244385 |
| | Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation | Q45262924 |
| | Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels | Q45280966 |
| | CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin | Q45292596 |
| | Intensive lipid lowering with atorvastatin in patients with stable coronary disease | Q45310626 |
| | Atorvastatin treatment affects atrial ion currents and their tachycardia-induced remodeling in rabbits | Q45585200 |
| | Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. | Q45915774 |
| | Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. | Q45999708 |
| | Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction. | Q46023579 |
| | Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis | Q46083169 |
| | Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. | Q46129738 |
| | Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins | Q46160875 |
| | Modulation of human T cells signaling transduction by lovastatin. | Q46220760 |
| | The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery | Q46460690 |
| | Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans | Q46468933 |
| | Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia | Q46489681 |
| | Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction | Q46515919 |
| | Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis | Q46610834 |
| | Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells | Q46618533 |
| | Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation | Q46881115 |
| | Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial | Q46930256 |
| | Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. | Q46957443 |
| | Statin treatment and 3' polyadenylation of eNOS mRNA. | Q46966122 |
| | Should patients with rheumatoid arthritis receive statin therapy? | Q47911347 |
| | Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings | Q48109395 |
| | Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis | Q50042365 |
| | Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. | Q51468245 |
| | Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial | Q51652663 |
| | Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. | Q51756404 |
| | Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. | Q52541795 |
| | Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. | Q53563884 |
| | Lovastatin inhibits proliferation and differentiation and causes apoptosis in lipopolysaccharide-stimulated murine B cells. | Q53776435 |
| | Statins reduce macrophage inflammatory protein-1alpha expression in human activated monocytes. | Q54565890 |
| | Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. | Q54629413 |
| | Early Withdrawal of Statin Therapy in Patients With Non–ST-Segment Elevation Myocardial Infarction National Registry of Myocardial Infarction | Q57631002 |
| | Stabilisation of atherosclerotic plaques | Q59260971 |
| | HMG-CoA Reductase Inhibitors Decrease Angiotensin II–Induced Vascular Fibrosis | Q61854913 |
| | Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration | Q63283505 |
| | HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease | Q73176738 |
| | Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells | Q73176746 |
| | Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC | Q73492434 |
| | Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study | Q74137245 |
| | A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial | Q74601678 |
| | Geranylgeranylpyrophosphate plays a key role for the G1 to S transition in vascular smooth muscle cells | Q74605604 |
| | Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase | Q77195720 |
| | Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial | Q77933067 |
| | Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration | Q77983928 |
| | RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin | Q79318156 |
| | Effects of pravastatin in murine collagen-induced arthritis | Q79375400 |
| | Rebound of inflammatory response after withdrawal of statins does not increases event rates in patients with stable cardiac disease | Q79824772 |
| | Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia | Q79917157 |
| | A pravastatin dose-escalation study in systemic lupus erythematosus | Q80089099 |
| | Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells | Q80139690 |
| | Effect of statin withdrawal on frequency of cardiac events after vascular surgery | Q80611211 |
| | The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells | Q81161461 |
| | Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients | Q82475373 |
| | Geranylgeranyl-pyrophosphate regulates secretion of pentraxin 3 and monocyte chemoattractant protein-1 from rheumatoid fibroblast-like synoviocytes in distinct manners | Q83463780 |
| | Adiponectin as a regulator of vascular redox state: therapeutic implications | Q83755590 |
| | Graft-protective effects of the HMG-CoA reductase inhibitor pravastatin after lung transplantation--a propensity score analysis with 23 years of follow-up | Q84464768 |
| | The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases | Q84565393 |
| | Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2. | Q33589158 |
| | Persistence with Statins and Onset of Rheumatoid Arthritis: A Population-Based Cohort Study | Q33691624 |
| | Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial | Q33940282 |
| | Rosuvastatin and cardiovascular events in patients undergoing hemodialysis | Q34016806 |
| | Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection | Q34088803 |
| | Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism. | Q34133687 |
| | Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). | Q34164324 |
| | Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra | Q34189543 |
| | Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial | Q34327988 |
| | Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities | Q34453538 |
| | Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial | Q34550538 |
| | The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial | Q34630074 |
| | Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins | Q34631666 |
| | Cardiovascular disease and osteoporosis: is there a link between lipids and bone? | Q34661617 |
| | Rosuvastatin in older patients with systolic heart failure | Q34710349 |
| | Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial | Q34817061 |
| | Endothelium-dependent effects of statins | Q35077362 |
| | Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? | Q35789870 |
| | Modulation of oxidant and antioxidant enzyme expression and function in vascular cells | Q35874787 |
| | Effect of pravastatin on cardiovascular events in people with chronic kidney disease | Q35886206 |
| | Statins in rheumatology | Q36318715 |
| | Emerging indications for statins: a pluripotent family of agents with several potential applications | Q37066246 |
| | Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy | Q37149829 |
| | Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment? | Q37294495 |
| | Targeting redox signaling in the vascular wall: from basic science to clinical practice | Q37370527 |
| | Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia | Q37376937 |
| | The CD40/CD40 ligand system: linking inflammation with atherothrombosis | Q37579360 |
| | Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. | Q37629827 |
| | Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling | Q37709733 |
| | The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review | Q37909189 |
| | Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial | Q38379296 |
| | The JUPITER trial: myth or reality? | Q38462688 |
| | Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evalu | Q38469055 |
| | Statin therapy for low-LDL, high-hsCRP patients: from JUPITER to CORONA. | Q38469099 |
| | Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction. | Q38493869 |
| | Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity | Q38499793 |
| | Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques | Q40625309 |
| | HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells | Q40670508 |
| | Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia | Q40860950 |
| | Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure | Q42151480 |
| | Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment | Q42447271 |
| | Statin islands and PPAR ligands in platelets | Q42557418 |
| | Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. | Q42829070 |
| | Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor γ. | Q42880722 |
| | Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues | Q43075890 |
| | Rosuvastatin and cardiovascular continuum when time is important | Q43105909 |
| | Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy | Q43164753 |
| | A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis | Q43167802 |
| | Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. | Q43234063 |
| | Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? | Q43255462 |
| | Immunomodulation by atorvastatin upregulates expression of gap junction proteins in coxsackievirus B3 (CVB3)-induced myocarditis | Q43272688 |
| | Inhibition of platelet-rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy | Q43295167 |
| | Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. | Q43794476 |
| | Withdrawal of statins increases event rates in patients with acute coronary syndromes | Q43933090 |
| | The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease | Q43934617 |
| | Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice | Q44007043 |
| | Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial | Q44036282 |
| | Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. | Q44063984 |
| | Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus | Q44249465 |
| | A novel anti-inflammatory role for simvastatin in inflammatory arthritis | Q44285429 |
| | Pitavastatin inhibits vascular smooth muscle cell proliferation by inactivating extracellular signal-regulated kinases 1/2. | Q44350940 |
| | Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans | Q44374274 |
| | 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats | Q44524073 |
| | Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin. | Q44551660 |
| | High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study | Q44585429 |
| | Statin treatment withdrawal in ischemic stroke: a controlled randomized study | Q44596876 |
| | Direct Anti-Inflammatory Mechanisms Contribute to Attenuation of Experimental Allograft Arteriosclerosis by Statins | Q44601106 |
| | Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study | Q44606908 |
| | Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries | Q44838824 |
| | Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study | Q44933960 |
| | Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia | Q44972878 |
| | Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins | Q45004040 |
| | Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. | Q45110342 |
| | Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients | Q45215872 |
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| | anti-inflammatory agent | Q581996 |
| | statin | Q954845 |
| | mechanism of action | Q3271540 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1519-1530 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Current Pharmaceutical Design | Q5195068 |
| P1476 | title | Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials | |
| P478 | volume | 18 | |